Page 196 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

172 Lindsay Lally and Stephen A. Paget

[9] Gherardi, R., Belec, L., Mhiri, C., et al. The spectrum of vasculitis in human
immunodeficiency virus-infected patients. A clinicopathologic evaluation. Arthritis
Rheum. 1993; 36:1164-1174.

[10] C. L. Koening C. L., Katz, B. J., Hernandez-Rodriguez, J., et al. Identification of a
Burkholderia-like strain from temporal arteries of subjects with giant cell arteritis.
Arthritis Rheum. 2012; 64:S373.

[11] Wiik, A. Drug-induced vasculitis. Curr. Opin. Rheumatol. 2008, 20:35-39.
[12] Weisner, O., Russell, K. A., Lee, A. S., et al. Antineutrophil cytoplasmic antibodies

reacting with human neutrophil elastatse as a diagnostic marker for cocaine-induced
midline destructive lesions but not auto-immune vasculitis. Arthritis Rheum. 2004; 50:
2954-2965.
[13] Weinberg, I., Jaff, M. R. Nonatherosclerotic arterial disorders of the lower extremities.
Circulation 2012; 126:213-222.
[14] Bendixen, B., Younger, D. S., Hair, L., et al. Cholesterol emboli syndrome: a patient
with peripheral neuropathy. Neurology 1992; 42; 428-430.
[15] Wooten, M. D., Jasin, H. E. Vasculitis and lymphoproliferative diseases. Semin.
Arthritis Rheum. 1996; 564-574.
[16] Musette, P., Labbaye, C., Dorner, M. H., et al. Wegener's autoantigen and leukemia.
Blood 1991; 77:1398-1399.
[17] Pinede, L., Duhaut, P., Loire, R. Clinical presentation of left atrial cardiac myxoma. A
series of 112 consecutive cases. Medicine 2001; 80:159-172.
[18] Beighton, P., De Paepe, A., Steinmann, B., et al. Ehlers-Danlos syndrome: revised
nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (US) and Ehlers-
Danlos Support Group (UK). Am. J. Med. Genet. 1998; 77:31-37.
[19] Kontusaari, S., Tromp, G., Kuivaniemi, H., et al. A mutation in the gene for type III
procollagen (COL3A1) in a family with aortic aneurysms. J. Clin. Invest. 1990; 86:
1465-1473.
[20] Pyeritz, R. E., McKusick, V. A. The Marfan syndrome. N. Engl. J. Med. 1979; 300:
772-777.
[21] Baer, R. W., Taussig, H. B., Oppenheimer, E. H. Congenital aneurysmal dilatation of
the aorta associated with arachnodactyly. Bull. Johns Hopkins Hosp. 1943; 72:309-331.
[22] Etter, L. E., Glover, L. P. Arachnodactyly complicated by dislocated lens and death
from rupture of dissecting aneurysm of the aorta. JAMA 1943; 123:88-89.
[23] Abraham, P. A., Perejda, A. J., Carnes, W. H., et al. Marfan syndrome: demonstration
of abnormal elastin in aorta. J. Clin. Invest. 1982; 70:1245-1252.
[24] Boileau, C., Guo, D.-C., Hanna, N., et al. TGFB2 mutations cause familial thoracic
aortic aneurysms and dissections associated with mild systemic features of Marfan
syndrome. Nature Genet. 2012; 44:916-921.
[25] Lindsay, M. E., Schepers, D., Bolar, N. A., et al. Loss-of-function mutations in TGFB2
cause a syndromic presentation of thoracic aortic aneurysm. Nature Genet. 2012; 44:
922-927.
[26] Grange, D. K., Balfour, I. C., Chen, S. C., et al. Familial syndrome of progressive
arterial occlusive disease consistent with fibromuscular dysplasia, hypertension,
congenital cardiac defects, bone fragility, brachysyndactyly, and learning disabilities.
Am. J. Med. Genet. 1998; 75:469-480.

Complimentary Contributor Copy